| 1 | | - | Senate Concurrent Resolution No. 61 CHAPTER 176Relative to public health. [ Filed with Secretary of State September 13, 2022. ] LEGISLATIVE COUNSEL'S DIGESTSCR 61, Dahle. Prostate Cancer Awareness Month.This measure would proclaim the month of September 2022 as Prostate Cancer Awareness Month.Digest Key Fiscal Committee: NO Bill TextWHEREAS, Prostate cancer is the most frequently diagnosed cancer in men aside from skin cancer. It is estimated that one in eight men will develop prostate cancer in their lifetime; and WHEREAS, The American Cancer Society estimates there will be approximately 268,490 new cases of prostate cancer in the United States in 2022, resulting in an estimated 34,500 deaths; and WHEREAS, It is estimated 26,890 men in California will be diagnosed with prostate cancer this year, and it is estimated that 4,130 men in California will die from this disease; and WHEREAS, Non-Hispanic Black men have the highest prostate cancer incidence rates in the world, and their prostate cancer mortality rate in the United States is more than twice that of any other ethnic group; and WHEREAS, Risk factors for prostate cancer include increasing age, African ancestry, a family history of the disease, and certain inherited genetic conditions; andWHEREAS, Having a father or brother with prostate cancer more than doubles a mans risk of developing the disease; and WHEREAS, Advanced prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, ribs, or other areas in the body; and WHEREAS, The prostate cancer death rate has been declining since the mid-1990s due to earlier detection through PSA testing and advances in treatment; andWHEREAS, The five-year survival rate approaches 100 percent when prostate cancer is diagnosed and treated early, but drops to 31 percent when it spreads to other parts of the body; and WHEREAS, Treatment options for prostate cancer vary depending on age, the stage and grade of cancer, and other existing medical conditions; and WHEREAS, The American Cancer Society recommends that men should have a conversation with their health care provider and should have an opportunity to make an informed decision about whether to be tested for prostate cancer based on personal values and preferences; and WHEREAS, For men who desire screening, prostate-specific antigen testing may begin at 55 years of age for average-risk men, and for men at higher than average risk, including Black men, men with a family history, men with a genetic predisposition, and veterans, testing should begin at 40 years of age; and WHEREAS, The cost of screening for early detection is a barrier that stifles detecting prostate cancer; now, therefore, be it Resolved by the Senate of the State of California, the Assembly thereof concurring, That the Legislature hereby proclaims the month of September 2022 to be Prostate Cancer Awareness Month in California; and be it further Resolved, That the Legislature urges all levels of government to provide an educational campaign to increase awareness about the importance for men to make an informed decision with their health care provider about early detection and testing for prostate cancer; and be it furtherResolved, That the Legislature joins communities across our nation to increase awareness about the importance of removing barriers to increase early detection and testing for prostate cancer so men can have the opportunity to make informed decisions with their health care provider about early treatment options; and be it further Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution. |
|---|
| 1 | + | Enrolled September 06, 2022 Passed IN Senate August 30, 2022 Passed IN Assembly August 04, 2022 Amended IN Assembly June 15, 2022 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Senate Concurrent Resolution No. 61Introduced by Senator Dahle(Coauthors: Assembly Members Aguiar-Curry, Alvarez, Arambula, Bauer-Kahan, Bennett, Berman, Bigelow, Bloom, Boerner Horvath, Mia Bonta, Calderon, Cervantes, Chen, Choi, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Davies, Flora, Fong, Mike Fong, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gray, Grayson, Haney, Holden, Irwin, Jones-Sawyer, Kalra, Lackey, Levine, Low, Maienschein, Mathis, Mayes, McCarty, McKinnor, Medina, Mullin, Muratsuchi, Nazarian, Nguyen, ODonnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Rendon, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Seyarto, Smith, Stone, Ting, Valladares, Villapudua, Ward, Akilah Weber, Wicks, Wilson, and Wood)August 24, 2021Relative to public health. LEGISLATIVE COUNSEL'S DIGESTSCR 61, Dahle. Prostate Cancer Awareness Month.This measure would proclaim the month of September 2022 as Prostate Cancer Awareness Month.Digest Key Fiscal Committee: NO Bill TextWHEREAS, Prostate cancer is the most frequently diagnosed cancer in men aside from skin cancer. It is estimated that one in eight men will develop prostate cancer in their lifetime; and WHEREAS, The American Cancer Society estimates there will be approximately 268,490 new cases of prostate cancer in the United States in 2022, resulting in an estimated 34,500 deaths; and WHEREAS, It is estimated 26,890 men in California will be diagnosed with prostate cancer this year, and it is estimated that 4,130 men in California will die from this disease; and WHEREAS, Non-Hispanic Black men have the highest prostate cancer incidence rates in the world, and their prostate cancer mortality rate in the United States is more than twice that of any other ethnic group; and WHEREAS, Risk factors for prostate cancer include increasing age, African ancestry, a family history of the disease, and certain inherited genetic conditions; andWHEREAS, Having a father or brother with prostate cancer more than doubles a mans risk of developing the disease; and WHEREAS, Advanced prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, ribs, or other areas in the body; and WHEREAS, The prostate cancer death rate has been declining since the mid-1990s due to earlier detection through PSA testing and advances in treatment; andWHEREAS, The five-year survival rate approaches 100 percent when prostate cancer is diagnosed and treated early, but drops to 31 percent when it spreads to other parts of the body; and WHEREAS, Treatment options for prostate cancer vary depending on age, the stage and grade of cancer, and other existing medical conditions; and WHEREAS, The American Cancer Society recommends that men should have a conversation with their health care provider and should have an opportunity to make an informed decision about whether to be tested for prostate cancer based on personal values and preferences; and WHEREAS, For men who desire screening, prostate-specific antigen testing may begin at 55 years of age for average-risk men, and for men at higher than average risk, including Black men, men with a family history, men with a genetic predisposition, and veterans, testing should begin at 40 years of age; and WHEREAS, The cost of screening for early detection is a barrier that stifles detecting prostate cancer; now, therefore, be it Resolved by the Senate of the State of California, the Assembly thereof concurring, That the Legislature hereby proclaims the month of September 2022 to be Prostate Cancer Awareness Month in California; and be it further Resolved, That the Legislature urges all levels of government to provide an educational campaign to increase awareness about the importance for men to make an informed decision with their health care provider about early detection and testing for prostate cancer; and be it furtherResolved, That the Legislature joins communities across our nation to increase awareness about the importance of removing barriers to increase early detection and testing for prostate cancer so men can have the opportunity to make informed decisions with their health care provider about early treatment options; and be it further Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution. |
|---|